Key Highlights Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2. Record operational momentum: CosmoFarm wholesale distribution and GMP-certified Cana contract manufacturing both delivering record volumes. Guidance signaling potential

Δίωρη στάση εργασίας και κινητοποίηση στην «Cosmofarm» πραγματοποίησε το πρωί της Τετάρτης το Συνδικάτο Φαρμάκου Αττικής, απαιτώντας να παρθεί πίσω η απόλυση εργαζόμενης «και να μην τολμήσουν να φέρουν νέα σύμβαση εργασίας με ευελιξία και Σάββατο».Όπως αναφέρει σε ανακοίνωσή του το Κλαδικό Συνδικάτο

CosmoFarm will deploy a multilingual voice platform with outbound automation and dashboards as Cosmos Health expands AI across front- and back-end operations.

Cosmos Health (NASDAQ:COSM) reported continued operational growth at Cosmofarm in 2025, adding nearly 100 new pharmacy customers (about a 20% weighted increase in active customer base). The business saw annual revenue per customer +12% and profitability per customer +14%, driven by improved route density, order execution and operational leverage. Cosmofarm added three new delivery routes in Attica and is upgrading a 29,000-square-foot Athens facility with expanded distribution and temperature-controlled storage. The company continues multi-year investments in ROWA and A-frame robotic systems and is executing an additional ~$1 million capital program to expand robotic capacity, supporting an incremental annual revenue potential of approximately $40 million as volumes scale.